|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZC3H7A |
Gene summary for ZC3H7A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZC3H7A | Gene ID | 29066 |
| Gene name | zinc finger CCCH-type containing 7A | |
| Gene Alias | HSPC055 | |
| Cytomap | 16p13.13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8IWR0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29066 | ZC3H7A | LZE4T | Human | Esophagus | ESCC | 1.16e-08 | 1.74e-01 | 0.0811 |
| 29066 | ZC3H7A | LZE7T | Human | Esophagus | ESCC | 3.50e-08 | 2.73e-01 | 0.0667 |
| 29066 | ZC3H7A | LZE20T | Human | Esophagus | ESCC | 7.11e-07 | 1.83e-01 | 0.0662 |
| 29066 | ZC3H7A | LZE24T | Human | Esophagus | ESCC | 1.62e-08 | 1.61e-01 | 0.0596 |
| 29066 | ZC3H7A | LZE21T | Human | Esophagus | ESCC | 5.72e-03 | 2.22e-01 | 0.0655 |
| 29066 | ZC3H7A | LZE6T | Human | Esophagus | ESCC | 2.81e-02 | 7.77e-02 | 0.0845 |
| 29066 | ZC3H7A | P1T-E | Human | Esophagus | ESCC | 7.08e-06 | 5.36e-01 | 0.0875 |
| 29066 | ZC3H7A | P2T-E | Human | Esophagus | ESCC | 6.01e-51 | 8.33e-01 | 0.1177 |
| 29066 | ZC3H7A | P4T-E | Human | Esophagus | ESCC | 2.86e-13 | 2.62e-01 | 0.1323 |
| 29066 | ZC3H7A | P5T-E | Human | Esophagus | ESCC | 3.25e-11 | 1.80e-01 | 0.1327 |
| 29066 | ZC3H7A | P8T-E | Human | Esophagus | ESCC | 8.61e-27 | 4.87e-01 | 0.0889 |
| 29066 | ZC3H7A | P9T-E | Human | Esophagus | ESCC | 1.96e-06 | 1.18e-01 | 0.1131 |
| 29066 | ZC3H7A | P10T-E | Human | Esophagus | ESCC | 2.57e-16 | 2.54e-01 | 0.116 |
| 29066 | ZC3H7A | P11T-E | Human | Esophagus | ESCC | 9.56e-09 | 4.37e-01 | 0.1426 |
| 29066 | ZC3H7A | P12T-E | Human | Esophagus | ESCC | 1.69e-29 | 4.72e-01 | 0.1122 |
| 29066 | ZC3H7A | P15T-E | Human | Esophagus | ESCC | 1.29e-22 | 4.75e-01 | 0.1149 |
| 29066 | ZC3H7A | P16T-E | Human | Esophagus | ESCC | 1.94e-25 | 5.30e-01 | 0.1153 |
| 29066 | ZC3H7A | P17T-E | Human | Esophagus | ESCC | 4.52e-05 | 3.51e-01 | 0.1278 |
| 29066 | ZC3H7A | P20T-E | Human | Esophagus | ESCC | 6.51e-35 | 7.51e-01 | 0.1124 |
| 29066 | ZC3H7A | P21T-E | Human | Esophagus | ESCC | 2.02e-13 | 2.37e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00351969 | Esophagus | ESCC | production of miRNAs involved in gene silencing by miRNA | 37/8552 | 52/18723 | 1.75e-04 | 1.14e-03 | 37 |
| GO:00310508 | Esophagus | ESCC | dsRNA processing | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:00709188 | Esophagus | ESCC | production of small RNA involved in gene silencing by RNA | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:003105021 | Liver | HCC | dsRNA processing | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
| GO:007091821 | Liver | HCC | production of small RNA involved in gene silencing by RNA | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
| GO:003519621 | Liver | HCC | production of miRNAs involved in gene silencing by miRNA | 36/7958 | 52/18723 | 8.79e-05 | 7.66e-04 | 36 |
| GO:00310507 | Oral cavity | OSCC | dsRNA processing | 31/7305 | 54/18723 | 4.66e-03 | 1.87e-02 | 31 |
| GO:00709187 | Oral cavity | OSCC | production of small RNA involved in gene silencing by RNA | 31/7305 | 54/18723 | 4.66e-03 | 1.87e-02 | 31 |
| GO:00351968 | Oral cavity | OSCC | production of miRNAs involved in gene silencing by miRNA | 30/7305 | 52/18723 | 4.84e-03 | 1.92e-02 | 30 |
| GO:003519622 | Oral cavity | EOLP | production of miRNAs involved in gene silencing by miRNA | 16/2218 | 52/18723 | 2.25e-04 | 2.22e-03 | 16 |
| GO:003105022 | Oral cavity | EOLP | dsRNA processing | 16/2218 | 54/18723 | 3.63e-04 | 3.32e-03 | 16 |
| GO:007091822 | Oral cavity | EOLP | production of small RNA involved in gene silencing by RNA | 16/2218 | 54/18723 | 3.63e-04 | 3.32e-03 | 16 |
| GO:003519616 | Thyroid | PTC | production of miRNAs involved in gene silencing by miRNA | 28/5968 | 52/18723 | 8.33e-04 | 5.13e-03 | 28 |
| GO:003105010 | Thyroid | PTC | dsRNA processing | 28/5968 | 54/18723 | 1.79e-03 | 9.68e-03 | 28 |
| GO:007091810 | Thyroid | PTC | production of small RNA involved in gene silencing by RNA | 28/5968 | 54/18723 | 1.79e-03 | 9.68e-03 | 28 |
| GO:003519617 | Thyroid | ATC | production of miRNAs involved in gene silencing by miRNA | 29/6293 | 52/18723 | 8.30e-04 | 4.57e-03 | 29 |
| GO:003105016 | Thyroid | ATC | dsRNA processing | 29/6293 | 54/18723 | 1.84e-03 | 9.03e-03 | 29 |
| GO:007091816 | Thyroid | ATC | production of small RNA involved in gene silencing by RNA | 29/6293 | 54/18723 | 1.84e-03 | 9.03e-03 | 29 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZC3H7A | SNV | Missense_Mutation | c.664N>T | p.Pro222Ser | p.P222S | Q8IWR0 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ZC3H7A | SNV | Missense_Mutation | novel | c.1862C>A | p.Ser621Tyr | p.S621Y | Q8IWR0 | protein_coding | deleterious(0) | benign(0.111) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| ZC3H7A | SNV | Missense_Mutation | novel | c.131G>T | p.Arg44Ile | p.R44I | Q8IWR0 | protein_coding | tolerated(0.07) | benign(0.142) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZC3H7A | SNV | Missense_Mutation | rs761429502 | c.2327A>G | p.Asn776Ser | p.N776S | Q8IWR0 | protein_coding | deleterious(0.02) | possibly_damaging(0.599) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZC3H7A | SNV | Missense_Mutation | c.2079N>C | p.Gln693His | p.Q693H | Q8IWR0 | protein_coding | deleterious(0.02) | possibly_damaging(0.885) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| ZC3H7A | SNV | Missense_Mutation | c.1450G>A | p.Asp484Asn | p.D484N | Q8IWR0 | protein_coding | tolerated(0.12) | possibly_damaging(0.638) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ZC3H7A | SNV | Missense_Mutation | rs764063084 | c.1358N>T | p.Ser453Leu | p.S453L | Q8IWR0 | protein_coding | deleterious(0) | benign(0.04) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ZC3H7A | SNV | Missense_Mutation | rs760553503 | c.775N>T | p.Val259Leu | p.V259L | Q8IWR0 | protein_coding | tolerated(0.69) | benign(0.005) | TCGA-LL-A5YL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| ZC3H7A | insertion | Frame_Shift_Ins | novel | c.2266_2267insACTTT | p.Trp756TyrfsTer4 | p.W756Yfs*4 | Q8IWR0 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| ZC3H7A | insertion | Nonsense_Mutation | novel | c.2119_2120insTACATTGTTAGAAACCATTAGGCAGACAACAAAGCC | p.Lys707delinsIleHisCysTerLysProLeuGlyArgGlnGlnSerGln | p.K707delinsIHC*KPLGRQQSQ | Q8IWR0 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |